The results establish Molexar as a practical unified foundation for computational chemistry and drug-design workflows and establish Molexar as a practical unified foundation for computational chemistry and drug-design workflows.
Abstract
Molecular generation is a central challenge in drug discovery, requiring models that explore vast chemical space while satisfying diverse design constraints. We present Molexar, a unified multimodal molecular foundation model built on Fragment-SELFIES, a robust, fragment-aware molecular language with validity-preserving decoding and explicit fragment structure. A pretrained autoregressive decoder learns the Fragment-SELFIES syntax and molecular distribution; supervised fine-tuning (SFT) then trains the same decoder on condition-molecule pairs spanning scalar molecular properties, pharmacophore fingerprints, protein sequences, and binding pockets, injecting each condition by in-place replacement of value-token embeddings so that all generation modes share one autoregressive path. Molexar achieves strong efficiency at a small parameter count while matching or exceeding larger models. The pretrained model reaches 100% validity and high drug-likeness in unconditional and fragment-constrained generation; the SFT model follows single- and multi-property instructions and remains competitive on target-conditioned generation on the CrossDocked2020 test set. On MolGenBench, Molexar further generates molecules with favorable safety and potency. These results establish Molexar as a practical unified foundation for computational chemistry and drug-design workflows.
PockLigGPT achieves competitive docking-oriented performance under a standardized evaluation protocol while maintaining chemical plausibility, favorable physicochemical profiles, and Lipinski-based drug-likeness.
Pablo Varas Pardo, Guillermo Marcos-Ayuso, Eugenia Ulzurrun et al.· Journal of Chemical Informat...· 0 citations
A new baseline method is developed identifying the critical components to solve the NMO tasks, including a novel representation for modeling structural constraints and a domain-agnostic pretraining strategy to eliminate pharmaceutical dataset bias.
Matthias Blaschke, Daniel Kienzle, Zsuzsanna Koczor-Benda et al.· arXiv.org· 0 citations
This study provides a large-scale empirical evaluation of multimodal feature fusion for molecular property classification by systematically integrating SMILES-based chemical language representations with fingerprint-based structural descriptors across 60 benchmark datasets.
Jing Liu, Li Xue, Yin Wang et al.· Journal of Cheminformatics· 0 citations
Vilya-1 is introduced, a deep learning model that addresses two central challenges in macrocycle design: sampling biologically relevant conformations across arbitrary chemistries and predicting key developability properties such as membrane permeability.
Vilya Research Pascal Sturmfels, M. Salem, Naozumi Hiranuma et al.· arXiv.org· 1 citation
Structure-based generative models (SBGMs) hold great promises for accelerating drug discovery by enabling target-aware molecular design. However, existing approaches face fundamental challenges: three-dimensional graph-based models can explicitly incorporate protein structural information but often generate chemically...
Bo Yang, Ke Xu, Chijian Xiang et al.· bioRxiv· 0 citations
This review elucidates the paradigm shift in drug discovery from serendipitous exploration to rational, structure-driven polypharmacological molecular engineering, thereby providing a clear, structured guide for navigating the complexities of next-generation therapeutics.
Tianming Han, Zhijie Pan, Wenchi Ge et al.· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.